Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2352 - Phase 1 expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Clinical Research

Tumour Site

Head and Neck Cancers


Hani Babiker


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


H.M. Babiker1, I. Brana2, D. Mahadevan3, T.K. Owonikoko4, E. Calvo5, D. Rischin6, V. Moreno7, K.P. Papadopoulos8, M. Crittenden9, S. Formenti10, J. Giralt11, P. Garrido Lopez12, A. Hervás Morón13, K.K. Mohan14, M.G. Fury14, I. Lowy14, E. Stankevich15, M. Feng15, J. Li16, M. Mathias14

Author affiliations

  • 1 Department Of Medicine, University of Arizona Cancer Center, 85724-5024 - Tucson/US
  • 2 Medical Oncology Department, Vall D’Hebron Institute of Oncology, Barcelona/ES
  • 3 The University Of Arizona Cancer Center, Formerly of The University of Tennessee Health Science Center and West Cancer Center, Memphis/US
  • 4 Department Of Hematology And Medical Oncology, Winship Cancer Institute, Emory University, 30322 - Atlanta/US
  • 5 Start Madrid, Centro Integral Oncológico Clara Campal, 28050 - Madrid/ES
  • 6 Department Of Medical Oncology, Peter MacCallum Cancer Centre, and the University of Melbourne, Melbourne/AU
  • 7 Start Madrid-fjd, Hospital Fundación Jiménez Díaz, 28040 - Madrid/ES
  • 8 Clinical research, START, 78229 - San Antonio/US
  • 9 Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center and The Oregon Clinic, 97213 - Portland/US
  • 10 Department Of Radiation oncology, Weill Cornell Medicine, 10065 - New York/US
  • 11 Radiation oncology Department, Vall d’Hebron University Hospital, Barcelona/ES
  • 12 Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 13 Department Of Radiology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 14 Clinical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown/US
  • 15 Clinical Sciences, Regeneron Pharmaceuticals, Inc., 07920 - Basking Ridge/US
  • 16 Biostatistics & Data Management, Regeneron Pharmaceuticals, Inc., 07920 - Basking Ridge/US

Abstract 2352


Most pts with R/M HNSCC do not respond to PD-1 inhibitor monotherapy. Cemiplimab is a human monoclonal anti-PD-1. An expansion cohort in the phase 1 study (NCT02383212) combined cemiplimab with other potential immune-supportive treatments for pts with R/M HNSCC.


Pts with R/M HNSCC who were refractory to at least first-line therapy and for whom palliative RT is clinically indicated received cemiplimab 3 mg/kg Q2W for up to 48 weeks plus RT (9 Gy × 3 times/week beginning 6–8 days after first dose of cemiplimab), cyclophosphamide (200 mg/m2 every 14 days for 4 doses), and GM-CSF (200 μg daily for 7-days after each of the first 4 doses of cemiplimab). The co-primary objectives were to characterise the safety, tolerability, and efficacy of cemiplimab in combination with RT, cyclophosphamide and GM-CSF in 15 pts with R/M HNSCC. Tumour assessments were performed by RECIST 1.1 Q8W.


As of 1 Sept, 2017, 15 pts (9 M/ 6 F) had been enrolled. Median (range) age was 62.0 (45–78) years; ECOG performance status was 1 in 12 pts (80%), and 0 in 3 (20%); and 14 (93.3%) had received prior RT. The primary site of cancer was upper aerodigestive tract of head and neck. With a median (range) duration of follow-up of 3.3 (0.5–10.2) months, treatment is ongoing in 3 pts (20.0%) and 12 (80%) had discontinued, mainly due to disease progression/recurrence (53.3%). The most common treatment-emergent adverse events (TEAEs) of any grade were fatigue (40.0%), constipation (26.7%), asthenia, dyspnoea, maculo-papular rash and pneumonia (each 20%). The only grade ≥3 TEAE that occurred in > 1 pts was pneumonia (13.3%). By investigator-assessment, there was 1 partial response (6.7%); disease control rate was 40.0% (95% CI: 16.3–67.7; 5 stable disease), 7 pts had progressive disease and 2 were not evaluable. Median progression-free survival by investigatorassessment was 1.8 months (95% CI: 1.7–4.7).


The combination therapy regimen did not demonstrate efficacy above that which can be achieved with PD-1 inhibitor monotherapy for R/M HNSCC.

Clinical trial identification


Legal entity responsible for the study

Regeneron Pharmaceutical, Inc.; Sanofi.


Regeneron Pharmaceutical, Inc.; Sanofi.

Editorial Acknowledgement

Medical writing support under the direction of the authors was provided by Emmanuel Ogunnowo, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc. and Sanofi according to Good Publication Practice guidelines (http://annals.org/aim/article/2424869/good-publication-practice-communicating-company-sponsored-medical-research-gpp3).


H.M. Babiker: Honoraria: Bayer, Sirtex; Consulting or advisory role fees: Celgene, Endocyte. D. Mahadevan: Speakers’ bureau and travel, accommodation expenses: Abbvie. T.K. Owonikoko: Fees for a consulting or advisory role: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune. E. Calvo: Research funding: Boehringer Ingelheim, Roche/Genentech, BMS, Novartis, PsiOxus, Nanobiotix, Janssen, Abbvie, PharmaMar, PUMA, Sanofi, Lilly, Pfizer, Merck, Nektar, Amcure, Amgen, AstraZeneca, Principia, Bayer, CytomX, H3, Incyte, Kura, loxo, Macrogenics, Menarini, Merck, Serono, Merus, Millenium, Rigontec, Tahio, TesaroReceipt; Honoraria/consultation fees: Novartis, Nanobiotix, Janssen-Cilag, PsiOxus Therapeutics, Seattle Genetics, Pierre Fabre, Boehringer Ingelheim, Cerulean Pharma, EUSA, Abbvie, Celgene; speaker’s bureau: Novartis. D. Rischin: Research funding: Genentech/Roche, Merck, Amgen, Regeneron, Bristol-Myers Squibb. M. Crittenden: Research funding: Jounce and Nanobiotix. P. Garrido: Personal fees: Roche, BMS, MSD, Pfizer, Lilly, Abbvie, Regeneron, AstraZeneca, Novartis, Boerinhger-Ingelheim, outside the submitted work. K.K. Mohan: Employee and shareholder: Regeneron Pharmaceuticals, Inc. M.G. Fury: Shareholder and an employee of, and holds patents, royalties, other intellectual property: Regeneron Pharmaceuticals, Inc. I. Lowy: Shareholder and employee of, and gained fees for travel and accommodation expenses as well as leadership: Regeneron Pharmaceuticals, Inc. E. Stankevich: Shareholder and employee: Regeneron Pharmaceuticals, Inc., Shareholder: Celgene, Bristol-Myers Squibb, Merck. M. Feng: Shareholder and employee: Regeneron Pharmaceuticals, Inc.; Shareholder: Bayer. J. Li, M. Mathias: Shareholder and employee: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.